Senhwa submitted multiple IND application to US FDA and Health Canada for the treatment of solid tumours

▴ Senhwa submitted multiple IND application to US FDA and Health Canada for the treatment of solid tumours
Senhwa announces multiple IND application submissions to US FDA and Health Canada evaluating its investigational drug, CX-5461, for the treatment of patients with solid tumours with BRCA2 or PALB2 mutations

Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, recently announced that it has submitted multiple Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA) and Health Canada evaluating its investigational drug, CX-5461, for the treatment of patients with solid tumours with BRCA2 or PALB2 mutations.

"This IND submission is a key milestone in the clinical development of CX-5461. In a phase I study conducted by Senhwa's clinical partner, Canadian Cancer Trial Group (CCTG), CX-5461 demonstrated clinically meaningful and lasting benefits in patients with specific tumor biomarkers that were resistant to platinum and other chemotherapeutics. The US and Canada clinical trials are being designed to further confirm the efficacy seen," said Dr John Soong, Chief Medical Officer of Senhwa Biosciences.

CX-5461 was recently named as a PCF-Pfizer Global Challenge Award recipient. Specifically, it will be used in combination with Pfizer's PARP inhibitor (PARPi), Talazoparib, to explore the therapeutic potential in prostate cancer, which is the second-leading cause of cancer death for men in the United States. In 2016, a recipient of the Stand Up to Cancer's Dream Team Grant selected CX-5461 to study in their Phase I trial. This study's clinical findings were featured in a spotlighted presentation at the 2019 annual San Antonio Breast Cancer Symposium. Due to the DNA repair defect, BRCA1/2 deficient tumour cells are more sensitive to PARPi through the mechanism of synthetic lethality. However, PARPi resistance is ubiquitous in clinic. More than 40% of BRCA1/2-deficient patients fail to respond to PARPi.

"CX-5461 is a first-in-class G-quadruplex stabilizer within a novel class of therapy that accelerates dsDNA breaks and has proven human efficacy across certain tumour types. We believe CX-5461 has great potential as a therapeutic for patients who have developed resistance to PAPRi or other chemotherapies. This continues to be an unmet medical need in cancer treatment," said Dr Tai-Sen Soong, CEO of Senhwa Biosciences.

CX-5461 is designed to stabilize DNA G-quadruplexes of cancer cells and leads to disruption of the cell's replication fork. While acting in concert with Homologous Recombination (HR) pathway deficiency, such as BRCA1/2 mutations, replication forks stall and cause DNA breaks, resulting in cancer cell death. CX-5461 in combination with Homologous Recombination Deficiency (HRD) tumours may be exploited through a synthetic lethality approach, targeting DNA repair defects in HRD tumours.

Tags : #SenhwaBiosciences #LatestNewsonSenhwaBiosciences26thNov #LatestPharmaNews26thNov #LatestNewsonCancerTreatment26thNov #HealthCanada #USFDA #CanadianCancerTrialGroup #PCF-PfizerGlobalChallengeAward #LatestNewsonProstateCancer26thNov #UnitedStates

About the Author

Team Medicircle

Related Stories

Loading Please wait...

Trending Now

“Early Detection of Rheumatoid Arthritis Can Help” by Dr.Rohit Chakor, Rheumatologist Specialist & Consultant Orthopedic Surgeon March 09, 2021
“Technology adds value to healthcare,” says Dr.Naresh Yallapragada, Chief Information Officer at Krishna Institute of Medical SciencesMarch 09, 2021
Behavioral Changes Towards Innovation in Technology is the Need of the Hour, says Bitopan Sarma Baruah, Head IT and Business Process, Excelcare HospitalsMarch 08, 2021
Keep It Simple, Keep it Local, says Kavita Bhatia, Clinical DietitianMarch 06, 2021
6 Top Women Entrepreneurs and CXOs are Transforming Healthcare for the BetterMarch 06, 2021
Top 4 reasons to visit a dentist today March 06, 2021
“Reframe your thoughts to prevent Dissociative Identity Disorder (DID)” by Dr.Sheereen K Bajpai, Expert Psychologist & Counselor from Indian Institute of Science Education and ResearchMarch 06, 2021
Digitalization Should Enable Clinicians to Focus on The Human Touch, says Dr. George Fernandes, CEO, Viveka HospitalsMarch 05, 2021
March 5 th 2021- Dissociative Identity Disorder(DID) Awareness DayMarch 04, 2021
Are You Struggling with “Maskne”? Find the Top 5 Solutions to deal with it. March 03, 2021
Exercise could well mimic the effects of Polypill , also it's cheaper and without side effectsMarch 03, 2021
Sorrento receives USFDA clearance to start a clinical trial of Anti-CD47 antibodyMarch 03, 2021
Regular breast checks by trained health workers linked to fewer breast cancer deaths in IndiaMarch 03, 2021
Treat Doctors as Friends and Have an Open Chat with Them says Dr. Shailaja Sabnis, Consultant Physician and Rheumatologist March 03, 2021
PM Jan Aushadhi Kendra inaugurated at District Hospital, KargilMarch 02, 2021
Maharashtra records 6,397 new cases of coronavirus todayMarch 02, 2021
One in four people will have hearing problems by 2050: WHOMarch 02, 2021
6 states show surge in Covid-19 cases, India's total active cases reach 1,68,627March 02, 2021
hday for longer life ; American Heart AssociationMarch 02, 2021
Is your baby cranky due to skin complaints? Here are some quick solutions that can help you.March 02, 2021